Publications
Other
Publication Date: April 7, 2025
This ISCT working group review concludes that no single technology suits every induced pluripotent stem cell (iPSC) therapy, so developers must match expansion and differentiation platforms to dose, batch size and analytics. It describes how early adoption of scalable, automated, closed processing lowers cost per batch and improves robustness, and how quality-by-design, design of experiment and process analytical technology support process understanding. A technology table covers platforms from T-flasks to stirred-tank reactors listed at up to 5000 L, and three hypothetical case studies illustrate choices: adherent culture for autologous retinal pigmented epithelium, a rocking motion bior…
Publications
CAR T Cells
Publication Date: April 3, 2025
Non-viral gene transfer, shorter manufacturing, off-the-shelf donor cells and decentralized point-of-care production are the main routes this review identifies for lowering the cost of CAR-T cell therapy, whose total expense can reach $2 million per treatment in the United States. A single-patient viral vector batch can cost more than $16,000. The authors' group produced CAR-T cells with transposons in under 24 hours; these cells were active against human B cell precursor leukemia in xenografted mice, with survival comparable to a conventional 8–12 day protocol. A three-day Novartis protocol combined with decentralized production cut the full process from 30 to 10 days, cells from one hea…
Publications
NK Cells
G-Rex®100M
Publication Date: April 1, 2025
A CD33 OR FLT3 NOT EMCN logic-gated CAR NK cell (SENTI-202 circuit) protected human hematopoietic stem and progenitor cells from off-tumor killing in a humanized mouse model. Mice engrafted with human HSC/HPCs received two CAR NK cell injections on day 0 and day 7, and HSC/HPC frequency was measured on day 14. Control iCAR NK cells lowered HSC/HPC frequency to 18.15% of hCD45+ cells versus 28.6% with non-engineered NK cells, whereas EMCN iCAR NK cells raised it to 34.2%. In vitro, the cells killed 50-70% of AML targets and preserved about 50% of EMCN-positive cells at an E:T ratio of 1:1. In the ongoing Phase 1 trial, HSPCs were increased or maintained in responders' bone marrow after tre…
Publications
TIL Cells
G-Rex®10M
Publication Date: March 12, 2025
Tumor-infiltrating lymphocytes can be expanded from soft tissue sarcoma and osteosarcoma without an anti-CD137 agonist antibody, using IL-2 and CD3/CD28 Dynabeads instead. Fragments of resected tumors from 11 patients were cultured with 6000 IU/mL IL-2 and beads for a pre-rapid expansion of 12 to 17 days in most samples, giving 1 × 10^6 to 9 × 10^6 cells per tissue. A subsequent two-week rapid expansion with OKT3, irradiated PBMC feeders and IL-2 gave 200- to 600-fold growth in 10 of 11 samples and favored CD8+ cells. Moving the rapid expansion to a G-Rex® 10M flask gave a further 2- to 3-fold gain over T-75 flasks. Expanded TILs reduced autologous tumor cell viability in vitro and slowed…
Publications
CAR T Cells, NK Cells
G-Rex®6 Well Plate
Publication Date: February 26, 2025
CD147-CAR-NK cells showed minimal toxicity toward healthy tissue expressing human CD147 and caused less neuroinflammation and memory impairment than CD147-CAR-T cells in a hepatocellular carcinoma mouse model. In vitro, CAR-NK cells killed SK-Hep1 tumor cells at more than 50% specific lysis, versus under 30% for liver and lung cells and under 40% for spleen cells from human CD147-transgenic NSG mice. Treated transgenic and wild-type mice did not differ in weight or survival over 53 days. CAR-NK cells persisted in tumor for up to 14 days, about one week longer than in non-tumor tissues. CAR-T-treated mice showed higher iNOS, and CAR-NK-treated mice scored better in Y-maze and novel object…
Publications
Other
Publication Date: February 25, 2025
Weakening the interaction between the TCR-binding domain of a Claudin 18.2-directed T cell antigen coupler (TAC) and CD3ε improved anti-tumor activity in mice. A humanized UCHT1 scFv carrying a Y54T substitution raised TAC surface expression and CD69 activation in primary T cells, and at a low dose of 1.0 × 10^6 cells it reduced tumor burden and extended survival in NALM6 leukemia and OE19 solid tumor models relative to the wild-type version. Biolayer interferometry showed the Y54T variant had the weakest affinity for CD3εδ (29.3 ± 4.0 nM versus 1.81 ± 0.63 nM for wild type), with a faster off-rate. The authors conclude that balanced, not maximal, TCR recruitment suits TAC design.
Publications
CAR T Cells, NK Cells, TCR T Cells, TIL Cells, Treg Cells
Publication Date: February 22, 2025
Automation of multi-step cell therapy manufacturing is reviewed by comparing eleven systems that can perform expansion alongside other steps, four used in clinical production and seven at research and development stage. The systems differ in whether they are all-in-one or modular, serial or parallel, how they ensure aseptic processing, and how much operator work remains. Reagent and vector preparation and quality sampling generally stay manual. Serial T-cell platforms such as CliniMACS Prodigy and Cocoon rely on one device per patient, which can limit scalability, whereas parallel designs could scale more readily. The authors conclude that no single solution fits all cell therapies and re…
Publications
Other
Publication Date: February 20, 2025
RESET, a two-component receptor that links rapamycin-dependent dimerization domains to an endogenous CD3 chain and a tumor-targeting subunit, gave T cells drug-controlled, highly sensitive antigen responses that exceeded those of CAR-T cells. Hinge, CD3 chain and domain-order variants were screened with a CD33-targeting nanobody, and the CD4 hinge with CD3ε was selected. RESET-T cells needed TCR expression, and their transcriptional profile resembled TCR-activated cells, whereas drug-regulated DARIC cells resembled CARs. RESET cells showed no observable activity without antigen, with or without rapamycin. In HL-60 xenografts, RESET-T cells controlled tumor better than DARIC-T cells, and i…
Publications
CAR T Cells
G-Rex®6M Well Plate
Publication Date: February 18, 2025
A circular Nanoplasmid carrying a single Cas9 target site, called Cas9-CLIPT, is linearized by the Cas9 ribonucleoprotein before electroporation and gave higher precise CAR knock-in at the TRAC locus in primary human T cells than a restriction-linearized control. On day 8, GD2 CAR knock-in was 61% versus 36% (1.7-fold), with over 98% TCR knockout, while fold expansion (8.8 versus 10.0) and viability did not differ significantly. The CAR T cells lysed GD2-positive neuroblastoma cells in vitro and were stem cell memory-like, with naive-central memory the largest subset at 37%. A larger inducible NFAT-mCherry construct (over 5 kb) reached 38% knock-in. On the Cellares automated electroporati…
Publications
NK Cells
G-Rex®100M, G-Rex®6M Well Plate
Publication Date: February 11, 2025
Arming umbilical cord blood-derived expanded natural killer (eNK) cells with Pin-EGFR, an Fc-engineered version of cetuximab, produced stronger, EGFR-specific killing of glioblastoma cells in vitro than unarmed eNK cells. One hour after arming, more than 80% of eNK cells carried the antibody and more than 40% remained armed after 3 days, whereas wild-type cetuximab did not stay bound. Armed cells increased cytotoxicity against U-87 MG and U-251 MG lines and against seven patient-derived glioblastoma cell lines, except the one with the lowest EGFR expression, while sparing healthy blood immune cells. The antibody anchored on the cells at a 3:1 effector-to-target ratio measured 1.5 ng/mL. W…
Publications
TCR T Cells
G-Rex®100M, G-Rex®24 Well Plate
Publication Date: February 10, 2025
Transient DNA-PK inhibition raised CRISPR/Cas9 knock-in efficiency of a T-cell receptor transgene at the TRAC locus of primary human T cells. Under standard research conditions, Thy1.1 reporter knock-in was 6.9% without inhibitor and reached 10.8% with PI-103 and 11.6% with samotolisib. In a GMP-compatible process, a five-hour inhibitor incubation after electroporation raised average tEGFR expression on day 9 from 22% to 45% with M3814, 34% with PI-103 and 38% with samotolisib, while CC-115 had no effect. Viability averaged 74% five hours after electroporation and fold expansion was unaffected by inhibitor treatment, with more than half of the cells remaining naive-like. Samotolisib-treat…
Publications
CAR T Cells
G-Rex®100M, G-Rex®6M Well Plate
Publication Date: January 31, 2025
A non-viral manufacturing process produced clinical-grade CD19-targeting CAR-T cells, TranspoCART19, by electroporating Sleeping Beauty transposon minicircles with SB100X transposase mRNA. Across four GMP validations run in two facilities from fresh and cryopreserved leukapheresis, the median expansion rate was 38.7 times, yielding an average of 3.9 x 10^9 total cells and 2.1-2.6 x 10^9 CAR-T cells with a median 60.2% CAR-positive and viability over 85%. All four products lysed more than 90% of NALM6 targets at a 2.5:1 effector-to-target ratio and were sterile, endotoxin and mycoplasma free. Vector copy number averaged 5.16 copies per cell, below the 15-copy release limit, with close-to-r…
No manuscripts match your filters.